It would be an absolute disgrace and embarrassment if MHRA approves this but not the FDA. You would have 80% of Americans with GBM flying to London every year to try and get this treatment, and the Swanston facility will likely still be at capacity.
Also, the valuation is not just about how much the drug could make in the next few years. The maturation of this technology could see revenues of a half-trillion dollars annually ~20 years down the road. The current claim is DCVax can be used to treat any solid state cancer, but they chose to test it on GBM since it's the most agressive. If that claim is true (and the data they have on that is likely being discussed behind closed doors in BO negotiations) there is unheard of value in this technology. Now, you're not going to get anywhere near that valuation for something with a 20 year lead time, but it very well needs to be taken into consideration with the price.
We are seeing a paradigm shift in how cancer will be treated. You get an actual quality of life with DCVax. Anyone who has ever seen a loved one go through chemo understands the value in that.
Anything less than $20 billion would be stealing the company, and I would vote 'no' as a shareholder to approve it. Fair valuation, in my opinion, would be $30bn to $60bn. That's a wide number range, and imho the difference will come down to how well DCVax has been performing in combo trials. If some of the rumors floating around twitter actually pan out, $60bn might actually be a reality. Will be very interesting to see if they present some combo data at SNO. If combo trials bump the survival rate another 10%, I think you'll see the $60bn number.
Bullish
AI
Market Data 
Markets 
